RxDoctor Payments Data

Nicole Chauvin, MD

Obstetrics & Gynecology · Baton Rouge, LANPI 1194900761

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (49.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 65.0% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $4,146, more than ten times the $286 reported in 2019. Among obstetrics & gynecology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,143in general payments, 2019–2025

Across 130 payments — averaging $47.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • AbbVie$414
  • Exeltis, USA Inc.$352
  • Avion Pharmaceuticals$226
  • Therapeuticsmd, Inc.$166
  • Lupin Inc.$140
  • plus $854 from 14 others

What the payments were for

  • Travel & lodging$99016%
  • Food & beverage$2,13435%
  • Education$3,01849%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,143 in reported general payments places this provider in the 90th percentile of 608 obstetrics & gynecology providers in Louisiana.

See all obstetrics & gynecology providers in Louisiana →

Medicare billing

Part B allowed, 2024
$8,917
Medicare patients
44
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremproEstrogen,con/M-Progest Acet13$3,204
Estradiol50$1,458
Risedronate Sodium17$1,186
Ibandronate Sodium12$295
Alendronate Sodium35$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPrempro$135$3,20413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 608 obstetrics & gynecology providers in Louisiana.

Other obstetrics & gynecology in Baton Rouge

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →